PHusis Therapeutics is a leading brand in the field of molecule therapeutics. They specialize in designing precision medicines using their proprietary computational modeling platform, PHuDock. This platform enables them to rapidly identify inhibitors of proteins with regulatory PH-domains that drive cancer growth.

With this approach, PHusis has built a pipeline of drug leads against some novel and critical cancer targets, including PDK1, mutant KRAS, and NRAS. The unique aspect of their small molecules PH-domain inhibitors is their improved toxicity profiles and the targeting of conventionally undruggable targets. They have two lead drug candidates that target lung and colon cancer, addressing the unmet needs in these markets.

Through their innovative methods, PHusis is able to identify and develop highly effective anticancer agents with low toxicity, setting a new standard in cancer drug development